Jim Cramer's Mad Money Lightning Round Picks, 8/16/07

Miriam Metzinger submits: Stocks discussed in the lightning round session of Jim Cramer’s Mad Money TV program, Thursday August 16. Click on a stock ticker for more analysis:

Bullish calls:

Total System (TSS): 'I think Total System is worth much more than $27.'
Crocs (CROX): 'will always keep some Crocs on hand ... I like the stock. It's had a nice pullback. It's having a nice quarter. ... I want to reiterate that Crocs is still in the growth phase. I'm not abandoning the story.'
Nastech Pharmaceutical (NSTK): 'That's the one you want to be in.'
Eagle Bulk Shipping (EGLE)
General Maritime (GMR): ' ... you know I like Gen-Mar.'
Apple (AAPL): 'I think Apple's come back enough. I like it. It's one of my four horsemen. I know it's been crushed.'
Terex (TEX): 'Terex is an inexpensive company that over the next few months is going to go up big.'
BioMarin Pharmaceutical (BMRN): 'That company is smoking. All the tests are good.'
International Game Technology (IGT): 'The way to play the big casinos. ... Great buybacks ... smart management. ... I think I'm gonna be right. I'm buying IGT. I'm sticking with IGT.'

Bearish calls:

QLogic (QLGC): 'They missed the quarter. We have so many tech stocks we like that are reporting great numbers. We do not need to go down the QLogic path.'
Cepheid (CPHD): 'I still think the stock is too high. I want to ring the register.'
Acadia Pharmaceuticals (ACAD)
Knight Transportation (KNX)
WMS Industries (WMS): 'I don't want you in that. It's not best of breed.'

Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and Wall Street Confidential Picks.

Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with CNBC, Jim Cramer or TheStreet.com

Comments

[jimmy Turano:]

EXPERT ON 'NSTK' What make someone an expert on nstk? Research? Knowledge?
I disagree with jim Cramer that 'nstk' is a stock to be in, especially in 2007. In looking at the three areas mentioned by Mr.cramer, obesity,autism, and Rnai I believe nstk is far behind in those areas and believe they will have great difficulties advancing in those areas too.*****In the Pipeline: Diabetes and Obesity Archives
Several companies have been working on PPAR alpha drugs for a long time now, and ... Novartis is the company in the lead, with a compound well into ...
corante.com/pipeline/a... - 23k - Cached
OBESITY DRUG NEARS APPROVAL*
www.drugtopics.com/dru...

AUTISM
Dr. Joseph Buxbaum heads up the Autism Genome Project at the Mount Sinai School of Medicine. 
www.msnbc.msn.com/id/7...
‘I think within ten years we'll have found the genes of major affect and most of the genes of minor affect. That will then lead to reasonable targets for drug interventions.’
— DR. JOSEPH BUXBAUM
Mount Sinai School of Medicine
Once genes are identified, there will be targets for drug intervention.
Jansen Pharmaceutica recently applied to the Food and Drug Administration for approval of its antipsychotic drug Risperdal for patients with autism.  It's the first time in history a pharmaceutical company has targeted autism as a disease.
“There are over a million and a half people with autism,” said Shestack. “And they have it from age 2 to age 70. And there is a tremendous opportunity for a company that wants to do well by doing good.”
**** 
What medications are available?
www.biotechwatch.com/k...
The most complex of all diseases and the most difficult to treat and get approval

Regarding: RNAI
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
biz.yahoo.com/bw/07073...

“Drug & Market Development Publications”
THE LEADING PROVIDER OF QUALITY LIFE SCIENCE MARKET ANALYSIS,OPPORTUNITY ASSESMENT, AND TACTICAL GUIDANCE
RNAi is the hottest topic in biotechnology and is positioned to revolutionize research and drug discovery.
Companies Profiled
Acuity Pharmaceuticals
AGY Therapeutics
Alnylam Pharmaceuticals
AntiSense Therapeutics
Benitec Australia
CytRx
Centa
Hemispherx Biopharma
International Therapeutics
Intragigm
ISIS Pharmaceuticals
Noxxon Pharma AG
Nucleonics
Sima Therapeutics
Alugen AG
Cenix BioScience
Compugen
Galapagos Genomics
Immusol
Ingenium Pharmaceuticals
Lexicon Genetics
Phenomix
Phylonix Pharmaceuticals
Zyogen
Amaxa
Ambion
CombiMatrix
Cyclacel
Cynellect
Dharmacon
Eurogentec
ExpressOn BioSystems
Gene Therapy Systems
Imgenex
Invitrogen
Mirus Bio
Ocimum Biosolutions
Plus more!
*LOOK AT THE COMPETITORS AND NOTICE ‘NSTK’ DIDN’T MAKE THE LIST**

POINT**I DO NOT MIND GETTING INFO THAT A STOCK MAYBE DEEMED NECESSARY TO INVEST IN.
IF THE INFORMATION THAT IS PROVIDED TO SHAREHOLDERS WEIGH IN THEIR FAVOR, THEN
FURTHER DD HOMEWORK IS WARRANTED FOR INVESTMENT CONSIDERATIONS.
HOWEVER, WHEN INFORMATION REGARDING A SPECIFIC COMPANY SEEMS TO GOOD TO BE TRUE, AND RESEARCH PROVES JUST THAT, THEN USING ONES AUTHORITY,CREDITABILTY...
TO PUT FORTH SUCH INACCURRACIES WHETHER BY MISTAKE OR FOR OTHER REASONS OF WHICH ARE INEXPLAINABLE, THEN ONE HAS TO WONDER WHY THIS WAS DONE IN SUCH A MATTER OF PURE HYPE! THERE LIES THE PROBLEM TO ALL SHAREHOLDERS!
IN CONCLUSION, IF THE THREE AREAS OF OBESITY, AUTISM, AND RNAI WAS PLAYED UP IN AN
EXAGERATING MANNER, THEN WHO BENEFITED THE MOST FOR THE RECOMMENDATION OF INVESTING ‘NOW’ IN 2007, IN NASTECH PHARMACEUTICAL?
Jimmy T

2007 Aug 20 10:27 AM

[jimmy Turano:]

SEPTEMBER 2, 2007
UPDATE-NSTK
FEUERSTEINS'S MAILBAG-A MUST READ!
Last article posted by seekingalpha was last April?

2007 Sep 02 08:52 AM

[jimmy Turano:]

September 1, 2007
The Feuerstein's mailbag article should extinguish the level of flames of hope in RNAI for NSTK and the other three areas touted by Mr.Cramer

2007 Sep 02 08:10 PM

[jimmy Turano:]

Feb.25,2008 My reply post to Cramer's article 8/18/07 has come to fruition. Today the stock is $2.02 vs Aug.16th close of $14.53.
BIG DIFFERENCE! BIG HYPE! BIG TOUT!
RESEARCH FIRMS ARE JUST AS GUILTY TOO.
JUST RECENTLY FRIEDMAN,BILLINGS,RAMS... GROUP
FINALLY DROPPED COVERAGE AND THEIR ANALYST ROBERT UHL IS GONE. BUT THE OTHER REMAINING RESEARCH FIRMS STILL HAVE NOT UPDATED THEIR RECOMMENDATIONS OR THEIR RIDICULOUS TARGET PRICES AS OF 02/025/08. WHY?
INVESTORS ARE STILL BEING MISLEAD AND NSTK CONTINUES TO MAKE NEW LOWS!

2008 Feb 25 06:44 AM